Melanoma treatment mystery gets new answers from mathematical model
New research from the University of Texas at Arlington helps explain a longstanding puzzle in melanoma treatment: why continuous targeted therapy performed better than planned on-and-off treatment schedules in clinical trials, despite promising laboratory studies of intermittent dosing.
New research from the University of Texas at Arlington sheds light on why continuous targeted therapy often outperforms intermittent treatment schedules in melanoma clinical trials, despite previous lab studies showing intermittent dosing could delay drug resistance. The study, published in Mathematical Biosciences, uses mathematical modeling to explain the discrepancy between lab findings and clinical results.
Traditionally, oncology treatments follow fixed dosing schedules, but the researchers found that adjusting treatment over time may be more effective in controlling tumors and reducing toxicity. Their analysis suggests an optimal strategy involves starting with full-dose therapy, then gradually tapering to an intermediate dose before discontinuing treatment altogether.
This approach aims to aggressively target drug-sensitive tumor cells early while minimizing opportunities for drug-resistant cells to develop. By providing computational tools, the study's goal is to guide treatment decisions and improve patient outcomes without replacing physicians' expertise. While the study focuses on melanoma, the mathematical framework could be adapted to other cancers where treatment effectiveness relies on balancing therapeutic benefit against toxicity.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
